•  Joint Replacement Procedures Continue Migrating to the ASC Setting
  
  • In 2023, SmartTRAK estimated that approximately 10% of all US hip and knee replacement procedures were performed in an ambulatory surgery center (ASC) setting. This trend shows no signs of slowing down. Based on recent procedure trends data, SmartTRAK projects ... (read more)
  • While procedure volumes at ASCs have risen, Medicare reimbursement rates continue to drop. SmartTRAK tracking of Medicare surgeon reimbursement shows ... (read more)
    
• Technology Trends: Streamlining, Personalization, Outcomes
  
  • Technology trends carrying over from 2024 include streamlining, personalization and outcomes. Some of the new products launching in 2025 are ... (read more)
• Potentially Disruptive Orthobiologic Therapies Coming to Market
  
  • New Orthobiologic injection therapies aim to better manage symptoms and modify disease progression in osteoarthritis (OA) patients. SmartTRAK feels this is ... (read more)
• Eight New Therapies on the Horizon That Could Impact Joint Replacement
  • Delaying surgeries by managing symptoms and  ... (read more)
  • Reducing the number of joint replacements performed: Advanced OA injectable therapies that more effectively target pain management could result in ... (read more)

Curious about the latest trends in the joint replacement market for 2025?    Click below to read her comprehensive market outlook article "Joint Replacement Trends to Watch in 2025" by Lisa Mahan, SmartTRAK's VP of Product Development & IT, Sr. Analyst Total Joints.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s plans to capture share and become the market leader in neurovascular.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s rebranding, plans for growth and becoming the market leader in neuroendovascular technologies in an interview with SmartTRAK. Listen to the video below to find out more, including how Terumo plans to innovate and take share via new disease states and markets in addition to its core neurovascular markets (ischemic, hemorrhagic and access).

Click on the video below to watch the interview (32:05 min). A link to download the complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

In 2024, SmartTRAK continued to empower you to Be The Expert in the MedTech industry. As your trusted resource for up-to-date industry insights, we delivered real-time market data, analysis and actionable insights across the orthopedics, wound care, regenerative medicine and neurotherapy markets. Here are SmartTRAK's Top Blog Posts from 2024, offering valuable perspectives from our expert analysts.

1. Skin Substitute Market Rocked by DOJ Investigations
   SmartTRAK believes the billions of dollars of Medicare abuse already uncovered is the tip of the iceberg in services billed to Medicare via the Physician Fee Schedule.
   
   
2. Medtronic: Making Waves At NANS 2024
   Medtronic executives discuss how the company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.
   
   
3. Spine Market Movers to Watch in 2024
   SmartTRAK highlights companies to watch as they continue their double-digit growth train with multiple catalysts for expansion in 2024.
   
   
   
   

On December 10, 2024, the Medicare Administrative Contractors (MACs) held a town hall session to discuss the Local Coverage Decisions (LCDs), “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers,” which were issued on November 14. The proposed LCDs were announced on April 25 of this year, a comment period followed, and then things went black as the MACs contemplated whether any changes should be made to the LCDs. Two key improvements in the final version included an increase in the number of skin substitute applications from four to eight and an increase in care time from 12 to 16 weeks. In this article, SmartTRAK will discuss the ongoing activities since these LCDs were announced, including the requirement for published peer-reviewed clinical evidence, market activities to shore up position and activities to rescind the LCDs. The article will close with SmartTRAK’s forward analysis of the impact of these LCDs on the market should they be implemented as planned.

Q’Apel Medical CEO Jodie Fam discusses the company, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at SVIN 2024. 

Q’Apel Medical CEO Jodie Fam discusses the company, its technologies, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at the Society of Vascular and Interventional Neurology (SVIN) held November 22-24, 2024 in San Diego, California. 

To find out more, click on the video below to listen to the interview (22:08 min). Click the button below to download a complete transcript of the interview.

In an interview with SmartTRAK, Gennaro Broya de Lucia, president of the National Board of Directors at PMI Sanità, offers a comprehensive summary of the challenges for the medical device market in Italy, which places hundreds of companies at risk in the country.